ARTHUR-D.-LITTLE
10.3.2021 09:02:06 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of seven of its consultants to the rank of Partner, in recognition of the expertise and depth of experience that each one brings to the company. These appointments represent a major milestone for ADL, with the company now boasting over 100 Partners within its global team. Over the past five years, ADL has doubled in size by pursuing a dynamic growth path, and one of the key tenets of its ongoing success is the development and promotion of its internal talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005042/en/
The latest appointments to Partner are as follows:
- Matteo Ainardi, Partner, Automotive and Manufacturing (AMG) and Strategy & Organization (S&O) Practices. Matteo joined ADL in 2016 and currently leads the company’s global Aerospace & Defense Center of Competence. His main focus is on supporting clients in the A&D ecosystem, focusing on strategy definition, organizational redesign and innovation management.
- Lokesh Dadhich, Partner, Telecommunication, Information, Media & Electronics (TIME) and Operations Management (OM) Practices. Lokesh joined ADL in 2007 and is based out of the company’s Dubai office. His main areas of expertise are in Digital Strategy, Customer Experience, and Operations Excellence topics. He advises clients in the TIME industry and beyond on strategy, operations, and transformation challenges.
- Naoya Furuta, Partner, Operations Management (OM) Practice. Naoya joined ADL’s Tokyo office as a Manager in 2016, and has experience across multiple industries, with a particular focus on manufacturing and construction. His main areas of expertise include company-wide strategic planning, corporate management, corporate reform, M&A advisory and PMI.
- Trung Ghi, Partner, Energy & Utilities (ENUT) Practice. With more than 20 years of experience in the oil and gas industry, Trung currently leads ADL’s ENUT Practice in South-East Asia, and has been responsible for opening a number of key accounts. He has been a driving force in positioning ADL as a go-to management consulting firm within SEA’s energy sector.
- Max Scherr, Partner, Strategy & Organization (S&O) Practice. With over 20 years of experience in strategy consulting as a senior executive, Max joined ADL in 2018 and leads the company’s S&O Practice in its Vienna office. His specializations include Digital Transformation, Information Security, Growth and Corporate Strategy.
- Ben Thuriaux-Alemán, Partner, Energy & Utilities (ENUT) and Technology & Innovation Management (TIM) Practices. With over 20 years of consulting experience, Ben has played a major role in developing ADL’s TIM Practice, and currently runs the company’s Global Innovation Excellence Benchmarking diagnostic. His particular focus is on aligning innovation with corporate strategy, and working on national innovation initiatives.
- Marten Zieris, Partner, Strategy & Organization (S&O) Practice. Marten joined ADL in 2010 and is based out of its Frankfurt office. He is responsible for the company’s competence center “Organization & Transformation” in Central Europe and supports international clients in large-scale transformations end to end, “from concept development to implementation”. Marten also has a specialist focus on consumer products businesses.
Ignacio García Alves, Chairman and CEO of Arthur D. Little, comments: “I would like to congratulate these new Partners – and welcome them as the first members of ADL’s ‘Generation 100’! Each promotion is richly deserved and a recognition of the vital contribution that each Partner makes to our company. At ADL, we strive to employ and develop consultants who are both entrepreneurs and team players, and aspire to deliver consultancy at the highest level – as such, having over 100 Partners within ADL truly is a momentous achievement.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom